| Figure 15. |
|
|
| The serotonin-2A receptor antagonist, MDL 100,907, enhances the potency of raclopride to inhibit avoidance behavior in rats (196) and also enhances the potency of raclopride to elicit catalepsy in rats (M.-L. Wadenberg, A. Young, P. Hicks and P. Seeman, to be published). Thus, the raclopride therapeutic "window" (i.e., dose between anti-avoidance and catalepsy) is not affected by the additional block of serotonin-2A receptors. |
published 2000